(2020’ IIT, 2022’ SIT Clinical trials are scheduled to be conducted)
MIUChon™ is a cellular therapeutic agent consisted of chondrocytes derived from homozygous iPSCs.
Unlike other cellular therapeutics, MIUChon™ is an injectable organoid-type osteoarthritis treatment.
We have CiSTEM's unique chondrocyte differentiation technology using induced pluripotent stem cells, and secured technology for high-quality chondrocyte production.
Research papers for the production and quality improvement of chondrocytes derived from induced pluripotent stem cells.